Q&A: Who Is Accountable When AI Gets Drug Development Wrong?

As AI becomes routine in drug development and manufacturing, attention is shifting from what the technology can do to what it can be trusted to do. In this second half of a discussion between BioPharm International® and Sanofi’s Matt Truppo, Open Biopharma’s Richard Jaenisch, and GxP Frame’s Brian Drapeau, the experts examine whether AI measurably improves the odds of therapeutic success, how companies keep human judgment and data governance at the center of AI-enabled work, and what success will look like in the near term. They also note what professionals entering the field should expect over the next 5 to 10 years.